ABAX 55.00 Abaxis Inc $ABAX Hit a 52 week high of 55.10

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 10:04 AM

ABAX 55.00 Abaxis Inc $ABAX Hit a 52 week high of 55.10 Closing the day 09:45 at 55.00 -0.01 -0.02% With a day low of 54.58 and a total volume of 15,788.

ABAX Recent Posts: http://investorshangout.com/Abaxis-ABAX-53195/

ABAX Abaxis Inc Recent Headline News

Strength Seen in Cerus (CERS): Stock Gains 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 38 mins ago
Cerus (CERS) was a big mover last session, with shares rising nearly 6% on the day.
CERS: 4.32 (-0.10), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch)

Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum
PR Newswire - 2 hrs 3 mins ago
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum on Thursday, November 20, 2014 at 8:00 a.m. ET. The conference will be held at The Westin Grand Central Hotel in New York City.
ABAX: 55.18 (+0.17)

Allscripts Healthcare and CHI Sign Hosting Solution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:40PM CST
By utilizing Allscripts Healthcare Solutions, Inc. (MDRX) Hosting Solution, Catholic Health Initiatives expects improved system availability, reduced IT infrastructure expenditures as well as enhanced end user performance.
GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17), MDRX: 12.62 (+0.16), MRGE: 3.06 (-0.03)

3 Stocks Going Ex-Dividend Tomorrow: ERH, PHT, ABAX
at The Street - Wed Nov 12, 9:52AM CST
ERH PHT ABAX are going ex-dividend tomorrow, Thursday, November 13, 2014
PHT: 17.73 (-0.03), ERH: 13.28 (-0.07), ABAX: 55.18 (+0.17)

Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.43 (+0.02), VIVO: 16.39 (-0.05), ABAX: 55.18 (+0.17), OSUR: 8.96 (unch)

INSYS Therapeutics (INSY) in Focus: Stock Rises 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:44AM CST
INSYS Therapeutics, Inc. (INSY) was a big mover last session, as the company saw its shares surge 12%
ICUI: 85.26 (+0.31), INSY: 38.80 (+0.09), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34)

Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch), OMER: 19.24 (-0.33)

Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference
PR Newswire - Wed Nov 12, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Don Wood, Chief Operating Officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 9:45 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.
ABAX: 55.18 (+0.17)

Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), OMCL: 32.60 (+0.04)

Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), BCR: 164.63 (-0.96), ABAX: 55.18 (+0.17)

Ex-Dividend Reminder: Abaxis, Chemed and AmerisourceBergen
DividendChannel.com - Tue Nov 11, 9:50AM CST
Looking at the universe of stocks we cover at Dividend Channel, on 11/13/14, Abaxis, Inc. , Chemed Corp , and AmerisourceBergen Corp.
ABAX: 55.18 (+0.17)

Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:46AM CST
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), EGRX: 12.65 (-0.15)

Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), WAG: 66.99 (+0.03)

Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.69 (+0.48), EBS: 24.15 (-0.17), ABAX: 55.18 (+0.17), ABBV: 63.26 (-0.37)

Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.39 (-0.05), ABAX: 55.18 (+0.17), GWPH: 75.50 (-0.34), OSUR: 8.96 (unch)

BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), BIOS: 5.79 (-0.07)

Allscripts Healthcare Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:30PM CST
Allscripts Healthcare Solutions, Inc. (MDRX) posted adjusted earnings of 2 cents per share in the third quarter of 2014 which missed the Zacks Consensus Estimate by 3 cents.
GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17), MDRX: 12.62 (+0.16), MRGE: 3.06 (-0.03)

Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.43 (+0.02), ICUI: 85.26 (+0.31), ABAX: 55.18 (+0.17), OMCL: 32.60 (+0.04)

SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 196.69 (+0.48), SRDX: 21.76 (+0.07), ABAX: 55.18 (+0.17), ABBV: 63.26 (-0.37)

Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.43 (+0.02), WMGI: 28.23 (-0.13), GWPH: 75.50 (-0.34), ABAX: 55.18 (+0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...